CN102056942B - 修饰的胱抑蛋白a支架蛋白 - Google Patents
修饰的胱抑蛋白a支架蛋白 Download PDFInfo
- Publication number
- CN102056942B CN102056942B CN200980122473.6A CN200980122473A CN102056942B CN 102056942 B CN102056942 B CN 102056942B CN 200980122473 A CN200980122473 A CN 200980122473A CN 102056942 B CN102056942 B CN 102056942B
- Authority
- CN
- China
- Prior art keywords
- protein
- polypeptide
- peptide
- guang
- albumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101710184528 Scaffolding protein Proteins 0.000 title claims abstract description 118
- 230000001629 suppression Effects 0.000 title claims abstract description 93
- 101710153593 Albumin A Proteins 0.000 title abstract description 116
- 230000004048 modification Effects 0.000 title description 36
- 238000012986 modification Methods 0.000 title description 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 307
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 100
- 229920001184 polypeptide Polymers 0.000 claims abstract description 48
- 108090000623 proteins and genes Proteins 0.000 claims description 120
- 102000004169 proteins and genes Human genes 0.000 claims description 119
- 230000035772 mutation Effects 0.000 claims description 81
- 150000001413 amino acids Chemical group 0.000 claims description 78
- 238000003780 insertion Methods 0.000 claims description 72
- 230000037431 insertion Effects 0.000 claims description 72
- 238000000034 method Methods 0.000 claims description 29
- 239000004475 Arginine Substances 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- 238000003825 pressing Methods 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 239000000090 biomarker Substances 0.000 claims description 3
- 238000011895 specific detection Methods 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 description 96
- 235000001014 amino acid Nutrition 0.000 description 68
- 230000008859 change Effects 0.000 description 64
- 108020004705 Codon Proteins 0.000 description 40
- 230000014509 gene expression Effects 0.000 description 32
- 238000004458 analytical method Methods 0.000 description 22
- 238000002983 circular dichroism Methods 0.000 description 22
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 20
- 241000588724 Escherichia coli Species 0.000 description 18
- 239000002253 acid Substances 0.000 description 16
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 15
- 108091034117 Oligonucleotide Proteins 0.000 description 15
- 230000003993 interaction Effects 0.000 description 15
- 230000008901 benefit Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 13
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 12
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 11
- 230000027455 binding Effects 0.000 description 11
- 238000002493 microarray Methods 0.000 description 11
- 108091008146 restriction endonucleases Proteins 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 230000004850 protein–protein interaction Effects 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 239000004471 Glycine Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 238000001114 immunoprecipitation Methods 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 230000004481 post-translational protein modification Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000007792 addition Methods 0.000 description 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 description 5
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 5
- 102000015833 Cystatin Human genes 0.000 description 5
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 230000008827 biological function Effects 0.000 description 5
- 108050004038 cystatin Proteins 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 230000006641 stabilisation Effects 0.000 description 5
- 238000011105 stabilization Methods 0.000 description 5
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108060008226 thioredoxin Proteins 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102000002933 Thioredoxin Human genes 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000009931 harmful effect Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000000869 mutational effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 101100189913 Caenorhabditis elegans pept-1 gene Proteins 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 102000005600 Cathepsins Human genes 0.000 description 3
- 108010084457 Cathepsins Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 108010079855 Peptide Aptamers Proteins 0.000 description 3
- 108020005038 Terminator Codon Proteins 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000001142 circular dichroism spectrum Methods 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 239000003596 drug target Substances 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000004853 protein function Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000000126 substance Chemical group 0.000 description 3
- 229940094937 thioredoxin Drugs 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- CQTGBCFGAAYOCY-ZCRNMIQFSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@@H](NC(C)=O)C(C)C)C(C)C)[C@@H](C)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C(C)C)C(N)=O CQTGBCFGAAYOCY-ZCRNMIQFSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- HSQGMTRYSIHDAC-BQBZGAKWSA-N Leu-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(O)=O HSQGMTRYSIHDAC-BQBZGAKWSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 102000019298 Lipocalin Human genes 0.000 description 2
- 108050006654 Lipocalin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 150000001875 compounds Chemical group 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 230000000368 destabilizing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 108010071185 leucyl-alanine Proteins 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 101710134784 Agnoprotein Proteins 0.000 description 1
- 108010011170 Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly Proteins 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 102100031491 Arylsulfatase B Human genes 0.000 description 1
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102220591835 Charged multivesicular body protein 3_V48D_mutation Human genes 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102220476904 Dynein regulatory complex protein 8_E78A_mutation Human genes 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Chemical group 0.000 description 1
- 101000921786 Homo sapiens Cystatin-A Proteins 0.000 description 1
- 101001104083 Homo sapiens Rabphilin-3A Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101710124584 Probable DNA-binding protein Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100040040 Rabphilin-3A Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 102000000395 SH3 domains Human genes 0.000 description 1
- 108050008861 SH3 domains Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QHNORJFCVHUPNH-UHFFFAOYSA-L To-Pro-3 Chemical compound [I-].[I-].S1C2=CC=CC=C2[N+](C)=C1C=CC=C1C2=CC=CC=C2N(CCC[N+](C)(C)C)C=C1 QHNORJFCVHUPNH-UHFFFAOYSA-L 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000003809 bile pigment Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 101150073031 cdk2 gene Proteins 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000008876 conformational transition Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000005518 electrochemistry Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000045247 human CSTA Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000003538 neomorphic effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 102220247477 rs1024182354 Human genes 0.000 description 1
- 102220242995 rs1555187010 Human genes 0.000 description 1
- 102220275989 rs1556435940 Human genes 0.000 description 1
- 102200041246 rs749465732 Human genes 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 108020005087 unfolded proteins Proteins 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (13)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0807065.8A GB0807065D0 (en) | 2008-04-18 | 2008-04-18 | Novel scaffolds |
GB0807065.8 | 2008-04-18 | ||
PCT/GB2009/050380 WO2009136182A1 (en) | 2008-04-18 | 2009-04-16 | Modified stefin a scaffold proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102056942A CN102056942A (zh) | 2011-05-11 |
CN102056942B true CN102056942B (zh) | 2017-05-31 |
Family
ID=39472316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200980122473.6A Active CN102056942B (zh) | 2008-04-18 | 2009-04-16 | 修饰的胱抑蛋白a支架蛋白 |
Country Status (12)
Country | Link |
---|---|
US (2) | US8853131B2 (zh) |
EP (1) | EP2279205B1 (zh) |
JP (1) | JP5688362B2 (zh) |
CN (1) | CN102056942B (zh) |
CA (1) | CA2757513C (zh) |
DK (1) | DK2279205T3 (zh) |
ES (1) | ES2602602T3 (zh) |
GB (1) | GB0807065D0 (zh) |
HU (1) | HUE031800T2 (zh) |
PL (1) | PL2279205T3 (zh) |
PT (1) | PT2279205T (zh) |
WO (1) | WO2009136182A1 (zh) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0807065D0 (en) * | 2008-04-18 | 2008-05-21 | Univ Leeds | Novel scaffolds |
JP5855094B2 (ja) | 2010-06-03 | 2016-02-09 | アイデックス ラボラトリーズ インコーポレイテッドIDEXX Laboratories, Inc. | 腎疾患のためのマーカー |
GB201302597D0 (en) | 2013-02-14 | 2013-04-03 | Univ Leeds | Novel Synthetic Proteins |
WO2017015630A2 (en) * | 2015-07-23 | 2017-01-26 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
WO2017127750A1 (en) | 2016-01-22 | 2017-07-27 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
ES2924223T3 (es) | 2017-01-04 | 2022-10-05 | Mgi Tech Co Ltd | Secuenciación de ácidos nucleicos mediante reactivos de afinidad |
WO2018135651A1 (ja) * | 2017-01-20 | 2018-07-26 | 国立大学法人埼玉大学 | 抗体-多糖結合体及びそれを用いた高感度免疫測定方法 |
KR102582297B1 (ko) | 2017-05-19 | 2023-09-25 | 필립모리스 프로덕츠 에스.에이. | 대상체의 흡연 상태를 구별하기 위한 진단 테스트 |
GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
IL311536A (en) * | 2018-06-04 | 2024-05-01 | Tufts College | Binder-drug conjugates activated in the microenvironment and their related uses |
CN108959846B (zh) * | 2018-07-03 | 2021-09-14 | 南昌立德生物技术有限公司 | 一种计算机辅助先导药物优化设计的亲和自由能分解算法 |
EP3932934A4 (en) | 2019-02-27 | 2023-09-20 | National University Corporation Tokyo Medical and Dental University | FUSION PROTEIN OF AN ANTIGEN-BINDING PROTEIN AND FLUORESCENT PROTEIN OR FLUORESCENCE-LABELED PROTEIN |
KR20220110181A (ko) * | 2019-10-09 | 2022-08-05 | 에드워드 프리츠 | 다중-도메인 단백질 백신 |
CN114761431A (zh) * | 2019-10-16 | 2022-07-15 | 株式会社Lg化学 | 新生儿Fc受体结合AFFIMER |
GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
TW202221030A (zh) * | 2020-07-30 | 2022-06-01 | 英商阿法克塔生命科學有限公司 | 血清白蛋白結合多肽 |
WO2023153876A1 (ko) * | 2022-02-10 | 2023-08-17 | 주식회사 아피셀테라퓨틱스 | Cd40l에 특이적으로 결합하는 스테핀 a 단백질 변이체 및 이의 용도 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006131749A2 (en) * | 2005-06-10 | 2006-12-14 | Medical Research Council | Scaffold |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0807065D0 (en) * | 2008-04-18 | 2008-05-21 | Univ Leeds | Novel scaffolds |
-
2008
- 2008-04-18 GB GBGB0807065.8A patent/GB0807065D0/en not_active Ceased
-
2009
- 2009-04-16 CA CA2757513A patent/CA2757513C/en active Active
- 2009-04-16 PL PL09742378T patent/PL2279205T3/pl unknown
- 2009-04-16 ES ES09742378.4T patent/ES2602602T3/es active Active
- 2009-04-16 WO PCT/GB2009/050380 patent/WO2009136182A1/en active Application Filing
- 2009-04-16 CN CN200980122473.6A patent/CN102056942B/zh active Active
- 2009-04-16 JP JP2011504541A patent/JP5688362B2/ja active Active
- 2009-04-16 EP EP09742378.4A patent/EP2279205B1/en active Active
- 2009-04-16 PT PT97423784T patent/PT2279205T/pt unknown
- 2009-04-16 DK DK09742378.4T patent/DK2279205T3/en active
- 2009-04-16 US US12/988,106 patent/US8853131B2/en active Active
- 2009-04-16 HU HUE09742378A patent/HUE031800T2/en unknown
-
2014
- 2014-09-05 US US14/478,910 patent/US9447170B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006131749A2 (en) * | 2005-06-10 | 2006-12-14 | Medical Research Council | Scaffold |
Non-Patent Citations (2)
Title |
---|
Design and Validation of a Neutral Protein Scaffold for the Presentation of Peptide Aptamers;Robbie Woodman et al.;《J. Mol. Biol.》;20051007;第352卷(第5期);第1118-1133页 * |
Significance of the Highly Conserved Gly-4 Residue in Human Cystatin A;Kazunori Shibuya,et al.;《J. Biochem.》;19950101;第118卷(第3期);摘要,表1 * |
Also Published As
Publication number | Publication date |
---|---|
US8853131B2 (en) | 2014-10-07 |
WO2009136182A1 (en) | 2009-11-12 |
JP2011520786A (ja) | 2011-07-21 |
ES2602602T3 (es) | 2017-02-21 |
CN102056942A (zh) | 2011-05-11 |
PT2279205T (pt) | 2016-11-17 |
CA2757513A1 (en) | 2009-11-12 |
US9447170B2 (en) | 2016-09-20 |
US20160024184A1 (en) | 2016-01-28 |
DK2279205T3 (en) | 2016-12-05 |
PL2279205T3 (pl) | 2017-04-28 |
EP2279205B1 (en) | 2016-08-17 |
CA2757513C (en) | 2022-11-15 |
HUE031800T2 (en) | 2017-08-28 |
GB0807065D0 (en) | 2008-05-21 |
US20110053796A1 (en) | 2011-03-03 |
EP2279205A1 (en) | 2011-02-02 |
JP5688362B2 (ja) | 2015-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102056942B (zh) | 修饰的胱抑蛋白a支架蛋白 | |
JP7027495B2 (ja) | 微生物トランスグルタミナーゼ、その基質、およびその使用方法 | |
Pott et al. | Evolved sequence contexts for highly efficient amber suppression with noncanonical amino acids | |
Dente et al. | Modified phage peptide libraries as a tool to study specificity of phosphorylation and recognition of tyrosine containing peptides | |
JP2010539915A (ja) | 設計されたアルマジロリピートタンパク質 | |
Gold et al. | Engineering A-kinase anchoring protein (AKAP)-selective regulatory subunits of protein kinase A (PKA) through structure-based phage selection | |
JP4505439B2 (ja) | 糖濃度に対するシグナル強度の向上した蛍光標識蛋白質及びその用途 | |
Kwon et al. | Non‐natural amino acids for protein engineering and new protein chemistries | |
Li et al. | High-throughput profiling of sequence recognition by tyrosine kinases and SH2 domains using bacterial peptide display | |
Sharma et al. | T7 phage display as a method of peptide ligand discovery for PDZ domain proteins | |
Gomes et al. | Design of an artificial phage-display library based on a new scaffold improved for average stability of the randomized proteins | |
Li et al. | Selection of peptides that target the aminoacyl-tRNA site of bacterial 16S ribosomal RNA | |
Mathonet et al. | Active TEM‐1 β‐lactamase mutants with random peptides inserted in three contiguous surface loops | |
Lee et al. | High‐throughput screening for transglutaminase activities using recombinant fluorescent proteins | |
Gold et al. | Engineering AKAP-selective regulatory subunits of PKA through structure-based phage selection | |
Gübeli et al. | In Vitro-Evolved Peptides Bind Monomeric Actin and Mimic Actin-Binding Protein Thymosin-β4 | |
Watt et al. | Phylomer Libraries: A Rich Source of Peptide Hits in Phenotypic and Target-Directed Screens | |
WO2005050518A1 (ja) | 遺伝子および/又は蛋白質のデータベースを用いた相互作用マップの作成方法、ならびに、それを実現するためのソフトウエアおよび装置 | |
Pokhrel | Establishing the Roles of the DNA Binding Domains of Replication Protein A (RPA) | |
Struyvenberg | Engineering Class A Sortases: Activity and Selectivity of Hybrid and Ancestral Variants | |
Bolt | Characterizing Sortase A Mutants with Altered Binding Selectivity | |
Hostetler | A Genetically Encoded Fluorescent Amino Acid Reveals Protein Dynamics Regulating The Bacterial Dna Damage Response | |
Rachel | Illuminating biomolecules: shedding light on the utility of labeling using transglutaminases | |
Marcozzi | Harnessing phages for supramolecular and materials chemistry | |
Hultschig | Two-dimensional screening: towards establishing a novel technique to study biomolecular interactions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: APUTE SIKAN CO., LTD. Free format text: FORMER OWNER: UNIV. OF LEEDS Effective date: 20140625 Free format text: FORMER OWNER: MEDICAL RES COUNCIL Effective date: 20140625 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: British Weatherby. Applicant after: Avacta Life Sciences Ltd. Address before: British Liz Applicant before: Apte J Can Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: APUTE SIKAN CO., LTD. TO: AWEI KETA LIFE SCIENCE CO., LTD. |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20140625 Address after: British Liz Applicant after: Apte J Can Ltd. Address before: Yorkshire Applicant before: University OF LEEDS Effective date of registration: 20140625 Address after: Yorkshire Applicant after: University OF LEEDS Address before: Yorkshire Applicant before: University OF LEEDS Applicant before: MEDICAL RESEARCH COUNCIL |
|
GR01 | Patent grant | ||
GR01 | Patent grant |